Vijaya Diagnostic Centre Limited (NSE: VIJAYA) shares closed at ₹994.55, down about 1.0% intraday, on 13 February 2026 following release of the company’s Q3 FY26 earnings presentation. The stock traded within a range of approximately ₹977–₹1,002 on the session.
Market Capitalization
At market close, Vijaya Diagnostic Centre Limited’s market capitalization stood around ₹10,200–₹10,250 crore on Indian exchanges.
Latest Quarterly Results
For the quarter ended 31 December 2025 (Q3 FY26), Vijaya Diagnostic reported:
- Revenue from operations: ₹2,052.1 million, representing a 21.4% year-over-year increase versus Q3 FY25.
- Profit after tax: ₹431.8 million, a 22.3% year-over-year rise on the same period last year.
Full-Year Results Context
In the nine months ended 31 December 2025 (9M FY26), the company reported:
- Revenue from operations: ₹5,948.3 million, up 17.1% year-over-year compared with 9M FY25.
- Profit after tax: ₹1,250.5 million, up 14.8% year-over-year over the same period last year.
Annual figures for FY25, as presented in the slide deck, show continued revenue and profit growth compared with FY24, with revenue at ₹6,813.9 million and PAT at ₹1,437.9 million.
Business & Operations Update
The company’s Q3 FY26 presentation highlighted operational expansion in core and new markets. In the quarter:
- New diagnostic hub centres were commissioned in Phoolbagan and Diamond Harbour (West Bengal), and in Khammam & Nandyal.
- The existing West Bengal hubs launched in earlier quarters reached break-even ahead of schedule.
- Leadership additions included appointment of a Chief Financial Officer, Chief Technology Officer and Chief Operating Officer.
- Expansion of hub and spoke facilities and enhancement of online booking and home collection services were detailed.
M&A or Strategic Moves
The presentation confirmed the merger of Medinova Diagnostic Services Limited (Kolkata) effective from 1 April 2024, as ordered by a National Company Law Tribunal bench.
Equity Analyst Commentary
Institutional research referenced in market discussions on VIJAYA has noted the company’s expansion efforts and quarterly growth trends without issuing specific ratings or target price forecasts. Summary points include acknowledgment of sequential revenue improvement and expanded geographical footprint.
Guidance & Outlook
Company-issued slides highlighted areas to watch, including expansion of hubs and spokes across India, penetration into new markets, and operational efficiencies through network densification. No explicit quantitative guidance was included in the presentation.
Performance Summary
Vijaya Diagnostic shares closed lower on the day of the earnings release. Q3 FY26 revenue rose 21.4% YoY, and profit increased 22.3% YoY. Nine-month results also showed growth in both revenue and profit compared with the prior year. Operational expansion and leadership strengthening were featured as recent developments.